TD Cowen raised the firm’s price target on Krystal Biotech (KRYS) to $306 from $202 and keeps a Buy rating on the shares. The firm updated its model following the release of “robust” Phase 1/2 data on KB407 in cystic fibrosis, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech price target raised to $306 from $202 at TD Cowen
- Krystal Biotech price target raised to $288 from $272 at BofA
- Krystal Biotech price target raised to $320 from $309 at Citi
- Krystal Biotech price target raised to $288 from $217 at Clear Street
- Krystal Biotech price target raised to $310 from $240 at H.C. Wainwright